Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Tao Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4568-638X; OpenAlex author ID A5101961890. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. Co-author DOI 10.1016/j.canlet.2025.217497↗
  2. HGF/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR/NGF axis. Co-author DOI 10.1038/s41419-022-04799-5↗
  3. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. Co-author DOI 10.1016/j.biopha.2020.110116↗
  4. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. First author DOI 10.1155/2020/1868764↗
  5. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  6. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo. Co-author DOI 10.1016/j.csbj.2019.03.016↗
  7. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  8. Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. Co-author DOI 10.3892/ijo.2018.4573↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 8 shared papers, 2018–2025 · strength 0.93
  2. Weikun Qian · 8 shared papers, 2018–2025 · strength 0.93
  3. Wanxing Duan · 5 shared papers, 2018–2025 · strength 0.65
  4. Jiguang Ma · 5 shared papers, 2018–2025 · strength 0.58
  5. Liang Han · 4 shared papers, 2018–2025 · strength 0.57
  6. Ying Xiao · 5 shared papers, 2018–2022 · strength 0.51
  7. Jie Li · 4 shared papers, 2018–2020 · strength 0.36
  8. Junyu Cao · 4 shared papers, 2018–2019 · strength 0.33
  9. Cancan Zhou · 3 shared papers, 2018–2020 · strength 0.25
  10. Zheng Wang · 2 shared papers, 2020–2022 · strength 0.25
  11. Jiantao Mo · 1 shared paper, 2025 · strength 0.25
  12. Zheng Wang · 1 shared paper, 2025 · strength 0.25
  13. Jingtao Gu · 1 shared paper, 2025 · strength 0.25
  14. Liang Cheng · 3 shared papers, 2018–2019 · strength 0.24
  15. Zheng Wu · 2 shared papers, 2019–2020 · strength 0.20
  16. Jianjun Lei · 2 shared papers, 2019–2020 · strength 0.19
  17. Erxi Wu · 2 shared papers, 2018–2020 · strength 0.17
  18. Ke Chen · 2 shared papers, 2018–2019 · strength 0.15
  19. Liang Han · 2 shared papers, 2018–2019 · strength 0.15
  20. Liankang Sun · 2 shared papers, 2018–2019 · strength 0.15
  21. Yangyang Yue · 1 shared paper, 2020 · strength 0.11
  22. Wei Li · 1 shared paper, 2020 · strength 0.10
  23. Shan H. Shao · 1 shared paper, 2020 · strength 0.10
  24. Xuqi Li · 1 shared paper, 2020 · strength 0.10
  25. Yongtian Yu · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.